Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 5.2% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (AMLX) Market Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The market sentiment for the company has been positive, with recent developments and analyst recommendations pointing towards growth potential.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 5.2% on Jun 23, 2026 15:01

• AMLX saw a strong bullish movement during the recent session.
• A reputable investment firm maintained a Buy rating for AMLX and adjusted its target price to $23, suggesting a potential upside of 40.5%.
• Analysts anticipate positive earnings, with a consensus price target range of $20.00 to $25.00, mostly recommending a "Buy" for the stock.
• Technical analysis highlights encouraging stock price momentum, support and resistance levels, and buy signals from moving averages, all contributing to the recent bullish market movement.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MILNE GEORGE M JR

This document is a statement of changes in beneficial ownership of securities for George M. Milne Jr., a Director at Amylyx Pharmaceuticals. It confirms the filing of Form 4, which details changes in his holdings of company stock.

https://www.moomoo.com/news/notice/307487706/amylyx-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of

Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $23

Goldman Sachs has maintained a Buy rating for Amylyx Pharmaceuticals (AMLX.US) and increased its target price to $23. This revised target price suggests a potential upside of 40.5% from the company's previous closing price. The adjustment reflects Goldman Sachs' continued positive outlook on the pharmaceutical company.

https://www.moomoo.com/news/post/71732915/goldman-sachs-maintains-amylyx-pharmaceuticals-amlxus-with-buy-rating-raises

Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis

Amylyx Pharmaceuticals Inc (AMLX) has a current valuation score of 8.12, placing it 166 out of 389 in the Biotechnology & Medical Research industry. The company's P/E ratio is -10.55, which is significantly below its recent high and above its recent low. Other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.

https://www.tradingkey.com/markets/stocks/nasdaq-amlx/company-valuation

Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Amylyx Pharmaceuticals Inc (AMLX) has an earnings forecast score of 8.83, ranking 53rd in the Biotechnology & Medical Research industry. Analysts provide a consensus price target of $20.00, with a high of $25.00 and a low of $16.00, and predominantly recommend a "Buy" for the stock. The company's previous quarter's EPS was -$0.30, beating the market expectation of -$0.37, while the next quarter is projected at -$0.36.

https://www.tradingkey.com/markets/stocks/nasdaq-amlx/earnings

Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Amylyx Pharmaceuticals Inc (AMLX), detailing its current stock price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently has a price momentum score of 8.94 and is trading within a range suitable for swing trading. Technical indicators show a mix of neutral, buy, and sell signals, while moving averages predominantly indicate buy signals.

https://www.tradingkey.com/markets/stocks/nasdaq-amlx/technical

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.5% Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.0% Today

Silver ($XAG) Commodity Forecast: Down 7.5% Today

Aave ($AAVE) Crypto Forecast: Up 9.4% Today

Chemours Company (The) ($CC) Stock Forecast: Up 8.1% Today

SiteOne Landscape Supply Inc. ($SITE) Stock Forecast: Up 5.1% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.1% Today

Target Corporation ($TGT) Stock Forecast: Up 5.2% Today

Campbell Soup Company ($CPB) Stock Forecast: Up 5.1% Today

Lennar Corporation Class A ($LEN) Stock Forecast: Up 6.3% Today

Amylyx Pharmaceuticals Price History

21.04.2026 - AMLX Stock was up 5.5%

• The positive news of the peer-reviewed publication of Phase 2 trial data for AMX0035 in treating Wolfram syndrome likely fueled the bullish movement in AMLX stock. The results, showing stabilization or improvement in various health parameters, have increased investor confidence in the company's drug pipeline.
• The reaffirmation of a Buy recommendation by B of A Securities has further bolstered investor sentiment towards Amylyx Pharmaceuticals, suggesting optimism about the company's future performance.
• The filing of an amended Schedule 13G/A by Perceptive Life Sciences Master Fund, Ltd., reporting a significant passive stake in AMLX, may have also contributed to the bullish movement by signaling institutional investor interest and support in the company's potential growth prospects.

18.04.2026 - AMLX Stock was down 5.1%

• A bearish movement in AMLX stock today may be due to profit-taking by investors following a recent bullish trend.
• The positive announcement of Phase 2 trial results for AMX0035 in Wolfram syndrome might have already been factored into the stock price, resulting in limited upward momentum.
• Despite receiving a Buy recommendation from B of A Securities, it might not have been sufficient to override broader market sentiments or short-term trading strategies.
• Speculation surrounding the Phase 3 trial outcome for AVEXITIDE and a potential launch in 2027 could be fueling speculative actions, causing some investors to sell off their positions in the near term.

09.05.2026 - AMLX Stock was up 5.0%

• The increase in AMLX stock price today may be linked to the positive response following the news of directors receiving significant stock options, indicating a strong belief in the company's future performance.
• Ongoing stock option grants to key individuals within the company reflect a confidence in Amylyx Pharmaceuticals' long-term growth and success, which likely resonated positively with investors.
• Further adding to the optimistic sentiment, the announcement of a $6.5 million class action settlement for investors who acquired AMLX securities during a specific period could have provided stability and reassurance to the market, contributing to the upward movement in the stock.
• In summary, the combination of favorable internal developments like stock option grants and the resolution of legal matters through the settlement likely boosted investor confidence and drove the bullish trend in AMLX stock today.

15.04.2026 - AMLX Stock was down 5.6%

• The upcoming Phase 3 AVEXITIDE trial results in the third quarter failed to offset the negative impact of Amylyx Pharmaceuticals' Q1 2026 earnings miss, resulting in a significant drop in the stock price.
• Despite the favorable prospects for AVEXITIDE and the company's robust financial standing, the earnings miss brought forth investor worries regarding the current financial performance.
• Differing viewpoints on the valuation of Amylyx Pharmaceuticals emerged, as a DCF analysis suggested undervaluation while the P/B ratio indicated overvaluation, likely playing a role in the bearish market behavior as investors reevaluate the stock's true value.
• The substantial valuation discrepancy between the stock price and analyst predictions, notwithstanding the positive advancements with AVEXITIDE and strategic investments in R&D, might have intensified the downward momentum on AMLX shares.

10.05.2026 - AMLX Stock was up 7.0%

• The positive sentiment surrounding the company's presentation at ENDO 2026, where they discussed the burden of post-bariatric hypoglycemia (PBH) and the design of their Phase 3 LUCIDITY trial for avexitide, a promising GLP-1 receptor antagonist, could be a factor behind the bullish movement in AMLX stock.
• The grant of stock options to various directors, including George M. Milne Jr., Karen Firestone, Paul R. Fonteyne, and Bernhardt G. Zeiher, might have also influenced the positive market sentiment, indicating confidence in the company's future and potential growth.
• These stock options grants could be perceived by investors as a demonstration of commitment from the directors, aligning their interests with those of the company. This alignment likely contributed to boosting investor confidence in Amylyx Pharmaceuticals and driving the bullish movement in AMLX stock.

23.05.2026 - AMLX Stock was up 5.2%

• AMLX saw a strong bullish movement during the recent session.
• A reputable investment firm maintained a Buy rating for AMLX and adjusted its target price to $23, suggesting a potential upside of 40.5%.
• Analysts anticipate positive earnings, with a consensus price target range of $20.00 to $25.00, mostly recommending a "Buy" for the stock.
• Technical analysis highlights encouraging stock price momentum, support and resistance levels, and buy signals from moving averages, all contributing to the recent bullish market movement.

12.05.2026 - AMLX Stock was up 8.5%

• AMLX stock showed significant bullish momentum today.
• The positive market sentiment can be attributed to the excitement surrounding the upcoming Phase 3 readout for avexitide, focusing on PBH.
• Investors may view the company's emphasis on rare disease commercialization and potential ALS treatments favorably.
• Recent stock options grants to directors could be interpreted as a vote of confidence in AMLX's future, bolstering the overall optimistic outlook for the company.

11.05.2026 - AMLX Stock was down 5.0%

• Today's decline in AMLX stock could be linked to investors taking profits following a period of positive developments and excitement regarding the Phase 3 readout for avexitide expected in Q3 2026.
• The announcement of directors receiving a substantial number of stock options at a strike price of $14.31 per share might have also contributed to the stock's downward pressure, potentially raising concerns about dilution among current shareholders.
• Despite the promising advancements in the company's drug pipeline and commercial strategies, today's market sentiment could have been swayed by short-term factors leading to the bearish movement in AMLX stock.

05.05.2026 - AMLX Stock was up 6.0%

• Key proposals at the Annual Meeting of Stockholders, including the election of new directors and the ratification of the independent accounting firm, likely boosted investor confidence in the company's governance and strategic direction.
• Analysts' optimism about Amylyx Pharmaceuticals' growth prospects, particularly in the post bariatric hypoglycemia (PBH) and neurodegeneration pipeline, may have attracted investors looking for long-term opportunities in the pharmaceutical industry.
• Progress in the pivotal Phase III LUCIDITY trial for avexitide, alongside potential future revenues and a positive estimated fair value per share, could have contributed to the bullish sentiment surrounding AMLX stock today.

12.04.2026 - AMLX Stock was down 5.2%

• A Discounted Cash Flow (DCF) analysis suggests AMLX is significantly undervalued, but its Price-to-Book (P/B) ratio indicates overvaluation compared to industry peers.
• Despite positive developments like completing enrollment for a pivotal trial and initiating an Expanded Access Program, AMLX's stock is trading below consensus targets and fair value estimates, leading to a large valuation gap.
• Analysts have provided varied ratings on AMLX, reflecting differing outlooks on the company's stock performance.
• The overall bearish movement in the healthcare sector, as evidenced by other healthcare stocks experiencing significant decreases in the pre-market session, could have contributed to AMLX's downward trend today.

07.04.2026 - AMLX Stock was down 6.9%

• The decline in AMLX stock today could be linked to the anticipation of the company's first-quarter financial results, which are projected to show a per-share loss and no revenue. This financial performance may have disappointed investors.
• Furthermore, the market's reaction to the news about the upcoming Phase 3 LUCIDITY trial data for avexitide, crucial for the company's future valuation and cash position, may have added to the negative sentiment.
• Amylyx Pharmaceuticals' involvement in investor conferences could have also impacted market sentiment, as investors may be waiting for insights or updates from these events before making significant decisions regarding the stock.
• Overall, factors such as financial performance expectations, forthcoming trial data, and participation in investor conferences likely contributed to the bearish movement in AMLX stock today.

02.05.2026 - AMLX Stock was down 5.0%

• The recent downward trend in AMLX's stock may be linked to investors taking profits following a substantial price surge in the past year.
• While news of insider purchasing by director Karen Firestone was positive, market response may have been negative due to concerns about upcoming commercial launch obstacles and the requirement for additional capital for pipeline development.
• Uncertainties surrounding the success of the pivotal Phase III LUCIDITY trial for avexitide, a significant pipeline candidate, might also have contributed to the stock's decline.
• In conclusion, despite AMLX's strong long-term outlook with its innovative pipeline, short-term market sentiment and uncertainties could have influenced the current bearish movement.